Juno Therapeutics Inc

Juno Therapeutics — Investor Presentation (January 2016)

20 slides from Juno Therapeutics's investor presentation, Jan 11, 2016

  1. Slide 1: Exhibit 99.2

    / Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those exp

  3. Slide 3: Building the leading T cell company

    Building the leading T cell company Significant advances in CD19-directed product candidates with a go-to-market strategy defined in ALL and NHL Progress with best-in-class product candidates and platform Broad program in solid organ tumors in significant areas of unmet need Building platform and se

  4. Slide 4: Compelling evidence of rapid tumor shrinkage across multiple clinical trials

    Compelling evidence of rapid tumor shrinkage across multiple clinical trials Experience across three leukemia trials demonstrates 82%-100% complete remission rates Most recent strategy in NHL demonstrates 82% overall response rate and 64% complete response rate(1) Day 37 After CD19 CAR T Cells ALL P

  5. Slide 5: Significant progress with CD19-directed portfolio

    Significant progress with CD19-directed portfolio The Phase II ROCKET trial for JCAR015 is enrolling in adult relapsed or refractory ALL Multi-center Phase I JCAR017 trial in adult relapsed or refractory NHL is enrolling CLL is emerging as a potential near-term target market Manufacturing facility c

  6. Slide 6: Significant unmet need in B cell malignancies

    Significant unmet need in B cell malignancies 2015 U.S. Estimates(¹) Incidence Annual Deaths ALL NHL CLL 6,250 71,850 14,620 1,450 19,790 4,650 (1)American Cancer Society 2015; Leukemia & Lymphoma Society 2015

  7. Slide 7: Encouraging percentage of deep remissions with defined cell product

    Encouraging percentage of deep remissions with defined cell product Juno CD19 experience Goal Product Candidate Potential First-in-class JCAR015 Potential Best-in-class JCAR017 Translational JCAR014 Trial r/r Adult ALL N = 46 Evaluable = 45 r/r Pediatric ALL N = 37 Evaluable = 32 r/r Adult ALL N = 3

  8. Slide 8: JCAR014: Encouraging data in NHL

    Conditioning Regimen Flu/Cy Dose Level 2*105/kg N=3 2*106/kg N=11 2*107/kg N=4-6 Efficacy CR(1) 1/3 (33%) 7/11 (64%) 1/4 (25%) CR/PR 1/3 (33%) 9/11 (82%) 3/4 (75%) Toxicity Severe Cytokine Release Syndrome 0/3 (0%) 1/11 (9%) 3/6 (50%) Severe Neurotoxicity 1/3 (33%) 2/11 (18%) 4/6 (67%) JCAR014: Enco

  9. Slide 9: JCAR014: CLL emerging as a significant opportunity

    CRs in patients previously treated with ibrutinib JCAR014: CLL emerging as a significant opportunity Response Assessment Age 36 – 70 years Prior treatment (all treated patients): Median 7 regimens 2 failed prior allogeneic transplant All patients previously treated with ibrutinib (1)All CLL patients

  10. Slide 10: Best-in-class strategy

    Best-in-class strategy Multiple trials to generate translational insights Advanced manufacturing capabilities with leading cell selection reagents to control the T cell population Multiple strategies for optimizing cell signaling, including: co-stimulatory domains armored CARs gene editing small mol

  11. Slide 11: Multiple strategies to support best-in-class products

    Multiple strategies to support best-in-class products JCAR014 in ALL Disease-Free Survival animals humans Improving persistence Improving signaling CD19 / 4-1BBL armored CAR Years after Infusion Probability of DFS 0.0 0.5 1.5 1.5 2.0 0.0 0.2 0.4 0.6 0.8 1.0 No Flu (n=13) Flu (n=17) Censor For JCAR01

  12. Slide 12: JCAR018: Another important target in B cell malignancies

    Increasing selection pressure with goal to reduce relapse rate JCAR018: Another important target in B cell malignancies The two mechanisms for relapse with CD19 CAR T cells are loss of CAR T cells and loss of CD19 CD22-directed CAR addresses CD19 epitope loss CD22 has the potential to be used alone

  13. Slide 13: Applying CAR and TCR technology to solid organ tumors

    Four trials with an opportunity for key learnings in 2016 Applying CAR and TCR technology to solid organ tumors Demonstrate that T cells kill cancer – recent checkpoint inhibitor and tumor infiltrating lymphocytes data Demonstrate that T cells home to the tumor Understand and overcome how the tumor

  14. Slide 14: Active and planned programs in clinical development

    Active and planned programs in clinical development The first set of solid tumor targets WT-1 (TCR) AML / NSCLC 15 patients with relapsed / high-risk AML treated with TCR product candidate after HSCT Generally well tolerated; demonstrated safety, persistence and encouraging clinical activity Ongoing

  15. Slide 15: Driving technology investment

    Driving technology investment Research focus areas: IDENTIFY THE RIGHT TARGET AND BINDER IMPROVE PERSISTENCE DEFINE OPTIMAL CELL POPULATION / STATE MODULATE THE TUMOR MICROENVIRONMENT CLINICIAN-CONTROLLED THERAPIES FOCUS AREA Efficacy Safety Addressable population

  16. Slide 16: The importance of single cell sequencing

    The importance of single cell sequencing Next-generation single cell sequencing improves Juno’s capabilities We can interrogate 1-5 million individual cells per experiment in hours Identification of fully-human, natively paired TCRs and B cell receptors that can serve as CAR T binders Discovery of n

  17. Slide 17: Accelerating Juno's pipeline

    Accelerating Juno’s pipeline Generate fully human TCRs Full sequence, fully-human, thymus-screened, α/β paired TCRs for our engineered T cell products Simultaneously capture TCRs restricted by multiple HLA-alleles (“moving beyond HLA-A2”) Identify novel targets Find cancer antigen tissue through int

  18. Slide 18: Achieving global scale

    Achieving global scale Commercial Key hires made Manufacturing Infrastructure to support patient supply Celgene World-class ex-U.S. partner to get our product candidates to patients quickly and support clinical trials around the world Development Broad global reach across multiple lines of therapy F

  19. Slide 19: Program Description

    Program Description CD19: JCAR015 (Adult ALL and Adult NHL) Adult ALL Phase I Adult NHL (Post Autologous Tx) Phase I Adult ALL Phase II Pivotal Study CD19: JCAR017 (Pediatric ALL and Adult NHL) Pediatric ALL Phase I / II Adult NHL Phase I / II CD19: JCAR014 (Adult B Cell Malignancies) Adult B Cell M

  20. Slide 20: Juno's goals for value creation

    Juno’s goals for value creation Execute Leukemia Potential First in Class: JCAR015 Adult ALL Potential Best in Class: JCAR017 Ped ALL CD19- Disease: JCAR018 Human CD19: JCAR021 Transform Lymphoma JCAR017 JCAR014 PD-L1 Combination Beyond B Cell Malignancies to Solid Tumors Target Selection ROR-1 MUC-

Juno Therapeutics — Investor Presentation (January 2016) on 6ix